Sunday, July 6, 2025 7/6/2025

High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation Reader

Award Number: R01CA268440
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/14/2022
PERIOD OF PERFORMANCE END DATE: 12/31/2025

Group Awards By:

View Award Description

High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation Reader - PROJECT SUMMARY Lung cancer is the leading cause of cancer-related deaths in both men and women in the U.S and worldwide. There are more than 400,000 deaths of lung cancer worldwide each year, among which lung squamous cell carcinoma (LUSC) accounts for about 30%. However, no effective treatments for LUSC are available. LUSC is one type of non-small cell lung cancer (NSCLC) characterized by numerous DNA alterations, including frequent amplification of the 3q26 chromosomal segment. The 3q26 segment is noteworthy because it contains the YEATS domain containing 2 (YEATS2) gene, a gene that is frequently amplified in a number of human cancers, including LUSC (~50%), ovarian (28%), head and neck (25%), and esophagus cancers (25%). High YEATS2 mRNA expression is associated with a poor prognosis of NSCLC patients, indicating that YEATS2 may have a tumor-promoting role. YEATS2 is a stoichiometric subunit of the Ada-Two-A-Containing (ATAC) complex, a conserved metazoan histone acetyltransferase (HAT) complex. YEATS2 contains an evolutionally conserved YEATS domain. We previously showed that the YEATS domain of YEATS2 functions as a reader of histone acetylation and other types of histone acylation such as crotonylation. Importantly, disrupting the YEATS histone reading activity impairs the normal functions of YEATS2 and the ATAC complex, resulting in reduced histone acetylation, decreased target gene expression, and inhibition of cell growth and survival of NSCLC. These data demonstrate that the YEATS domain of YEATS2 is a potential drug target, and that targeting YEATS2 may provide a therapeutic approach for treating NSCLC and other types of cancer characterized by YEATS2 amplification. The objective of this proposal is to develop potent and specific inhibitors targeting the histone acylation binding activity of the YEATS domain of YEATS2. For this, we will (1) conduct a high-throughput screen to identify YEATS2 small-molecule inhibitors, and (2) evaluate and characterize hit compounds in in vitro and cell-based assays. Through the proposed studies, we expect to identify potent, specific YEATS2 YEATS domain chemical probes of different chemotypes. These compounds will provide the basis for further development of small molecules for targeted therapies. Likewise, the research community will be able to use these new inhibitors as important tools to understand the functions and mechanisms of YEATS2 in human cancers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $434,625 )
2025	2025	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Treatment Research	000	4	12/13/2024	NON-COMPETING CONTINUATION	$391,163
2025	2025	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Treatment Research	001	4	6/3/2025	NON-COMPETING CONTINUATION	$43,462
														Subtotal = $434,625

Issue Date FY: 2024 ( Subtotal = $412,895 )
2024	2024	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Treatment Research	000	3	12/26/2023	NON-COMPETING CONTINUATION	$391,163
2024	2024	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Treatment Research	001	3	4/17/2024	NON-COMPETING CONTINUATION	$21,732
														Subtotal = $412,895

Issue Date FY: 2023 ( Subtotal = $430,892 )
2023	2023	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Treatment Research	002	2	3/15/2023	NON-COMPETING CONTINUATION	$35,174
2023	2023	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Treatment Research	000	2	12/7/2022	NON-COMPETING CONTINUATION	$395,718
2023	2022	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Treatment Research	001	1	12/19/2022	NEW	$0
														Subtotal = $430,892

Issue Date FY: 2022 ( Subtotal = $445,463 )
2022	2022	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Treatment Research	000	1	1/14/2022	NEW	$445,463
														Subtotal = $445,463

Grand Total All Awards = $1,723,875

Top

All Categories

About

Search

Reports

Data Submission

Award Information

High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation Reader

Award Number: R01CA268440

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/14/2022

PERIOD OF PERFORMANCE END DATE: 12/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer